GNLX - GENELUX Corp
2.52
0 0%
Share volume: 131,516
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.52
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-14-2024 | 11-14-2024 | 03-28-2025 | 05-06-2025 | 11-05-2025 | 03-19-2026 | |
| Total revenue | 8.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 8.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 8.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 8.000 K | |
| -100.00% | nan% | nan% | nan% | inf% | ||||
| Operating expenses | 8.123 M | 6.892 M | 6.941 M | 9.748 M | 7.816 M | 8.194 M | 9.420 M | |
| Selling general and admin | 4.113 M | 2.475 M | 2.890 M | 3.228 M | 3.118 M | 3.453 M | 3.766 M | |
| Research and development | 4.010 M | 4.417 M | 4.051 M | 6.520 M | 4.698 M | 4.741 M | 5.654 M | |
| Total expenses | 8.123 M | 6.892 M | 6.941 M | 9.748 M | 7.816 M | 8.194 M | 9.420 M | |
| -15.15% | 0.71% | 40.44% | -19.82% | 4.84% | 14.96% | |||
| Operating income | -8.115 M | -6.892 M | -6.941 M | -9.748 M | -7.816 M | -8.194 M | -9.412 M | |
| Ebit | -8.115 M | -6.892 M | -6.941 M | -8.621 M | -7.676 M | -8.125 M | -9.375 M | |
| Pretax income | -7.850 M | -6.576 M | -6.467 M | -8.976 M | -7.492 M | -7.950 M | -9.247 M | |
| -16.23% | -1.66% | 38.80% | -16.53% | 6.11% | 16.31% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -7.850 M | -6.576 M | -6.467 M | -8.976 M | -7.492 M | -7.950 M | -9.247 M | |
| 16.23% | 1.66% | -38.80% | 16.53% | -6.11% | -16.31% |